We describe a case of relapsed intravascular lymphomatosis (IVL) successfully treated with autologous PBSCT. A 59-year-old Japanese female patient with IVL who had achieved CR after six courses of biweekly CHOP therapy developed lymphoma. She achieved a second CR after six courses of modified biweekly CHOP therapy, followed by autologous PBSCH and high-dose chemotherapy (CBDCA, VP-16, MCNU, CY) with PBSCT. There has not been any evidence of recurrence 48 months after PBSCT. Our case suggests that PBSC is acceptable as a source for stem cell rescue in IVL. Bone Marrow Transplantation (2001) 27, 89-91.
Intravascular lymphomatosis (IVL) is a rare lymphoma subtype characterized by a proliferation of malignant lymphoid cells within vascular lamina. 1 IVL is generally sensitive to chemotherapy, although there are a few reported cases of long-term remission. 2 High-dose chemotherapy with autologous PBSCT is now widely adapted for relapsed NHLs. It is not known whether PBSCT is curative for IVL, because large numbers of neoplastic cells exist in systemic peripheral vessels. In this report, we describe the first recorded case of relapsed IVL successfully treated with autologous PBSCT.
Case report
A 59-year-old Japanese woman was admitted to Mie University Hospital in December 1994 with high fever, dyspnea and abnormal liver function. Five months before admission, she had consulted another hospital because of wheezing. A tentative diagnosis of bronchial asthma was made, and she was treated with corticosteroids. Her On physical examination, the patient demonstrated hepatosplenomegaly, with no lymphadenopathy. Peripheral blood count revealed a WBC of 1.05 ϫ 10 9 /l, RBC 2.95 ϫ 10 12 /l, hemoglobin 9.1 g/dl, and a platelet count of 33 ϫ 10 9 /l. Blood chemistry results were as follows: AST 61 IU, ALT 104 IU, LDH 488 IU (Ͻ225), ALP 639 IU, ␥-GTP 310 IU, and total bilirubin 0.8 mg/dl. Serum ferritin was elevated at 5250 ng/dl. Serum HTLV-1 and HIV antibodies were negative. Bone marrow examination revealed hypocellularity of all cell lines and no infiltration by lymphoma cells. Hemophagocytosis was noted. CT examination revealed marked hepatosplenomegaly and no lymphadenopathy. Biopsy of the liver showed a few large atypical lymphoid cells in the hepatic sinusoids. The patient was diagnosed as having IVL. She received six courses of biweekly CHOP chemotherapy. Her symptoms and the abnormal laboratory findings rapidly normalized. She was discharged from hospital in July 1995. Two months after discharge, high fever, dyspnea, hepatosplenomegaly and disorientation developed. She was readmitted to hospital and a peripheral blood count revealed a WBC of 4.36 ϫ 10 9 /l, RBC 2.90 ϫ 10 12 /l, hemoglobin 9.3 g/dl, and a platelet count of 69 ϫ 10 9 /l. Blood chemistry results were as follows: AST 109 IU, ALT 57 IU, LDH 674 IU, ALP 1030 IU, ␥-GTP 456 IU, and total bilirubin 4.4 mg/dl. The serum ferritin was 800 ng/dl. Titers against EBV were VCA IgG ϫ 80, VCA IgM Ͻ ϫ 10, EA IgG Ͻ ϫ 10, EA IgM Ͻ ϫ 10, and EBNA ϫ 10. Bone marrow examination revealed hypocellularity of all cell lines and no infiltration by lymphoma cells. Hemophagocytosis was not noted. Liver biopsy was performed again, and the histologic findings confirmed the diagnosis of IVL (Figure 1 ). Immunohistochemical staining on frozen sections revealed that the lymphoma cells had a B cell phenotype,
− and the surface immunoglobulin was M-lambda. Neoplastic cells were found to be negative for EBER by in situ hybridization. She was treated with five courses of modified biweekly CHOP therapy. The symptoms and abnormal laboratory data again rapidly returned to normal after therapy ( Figure  2 ). There were no atypical cells in the liver biopsy specimen obtained after therapy, and her disease was judged Transplantation was complicated by MRSA-induced colitis and herpes zoster, which resolved completely with appropriate treatment. Her WBC count reached 0/l on day +5 and by day +11 it was greater than 1.0 ϫ 10 9 /l. She was platelet independent from day +40. She was discharged from hospital on day +65 and is doing well with no evidence of recurrence 48 months after PBSCT.
Discussion
The prognosis of IVL has been considered poor. An earlier review of 86 patients with IVL reported a median survival of 5 months. 3 More recently, DiGiuseppe et al 2 reported that five patients with IVL treated with aggressive combination therapies have achieved long-term survival (Ͼ36 months) and are presumed cured. They also reported that all four patient who relapsed after achieving CR had died of disease. 2 For patients with relapsed but chemotherapysensitive NHLs, high-dose chemotherapy with stem cell transplantation is now widely used. Rose et al 4 reported the first case of IVL treated successfully with autologous BMT. They recommended marrow as the source of CD34 + cells rather than peripheral blood because of the singular localization of this lymphoma. We chose PBSC as a stem cell source because of the patient's age. Our patient remains well, in long-term remission, suggesting that PBSC, instead of marrow, can be an acceptable source of stem cells in IVL. Quantitative studies of minimal residual disease will confirm the feasibility of PBSC in transplantation for IVL.
